- Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis2022 | First Faculty of Medicine
- Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS2019 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.2009 | First Faculty of Medicine
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS2017 | First Faculty of Medicine
- Disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis2005 | First Faculty of Medicine
- Sex-specific disease modifiers in juvenile myoclonic epilepsy2022 | Second Faculty of Medicine
- Disease-modifying treatment approaches in Huntington disease: Past and future2022 | First Faculty of Medicine
- Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs2012 | First Faculty of Medicine
- Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis2022 | First Faculty of Medicine
- Therapy of rheumatoid arthritis with synthetic and biological disease modifying drugs.2009 | First Faculty of Medicine
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years2021 | First Faculty of Medicine
- Design, synthesis, and biological evaluation of 1-benzylamino-2-hydroxyalkyl derivatives as new potential disease-modifying multifunctional anti-Alzheimer's agents2018 | Publication without faculty affiliation
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study2019 | First Faculty of Medicine
- Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination2022 | First Faculty of Medicine
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis2019 | First Faculty of Medicine
- Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment2014 | First Faculty of Medicine
- Adverse Events of Drugs Used in Therapy or Rheumatic diseases - I. Disease Modifying drugs Used in the Therapy of Rheumatoid Arthritis and Basic Principals of Monitoring of Safety2003 | First Faculty of Medicine
- Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study2016 | First Faculty of Medicine
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study2019 | First Faculty of Medicine
- Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA2010 | First Faculty of Medicine
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | First Faculty of Medicine
- Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration2018 | First Faculty of Medicine
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs2010 | First Faculty of Medicine
- Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis2007 | First Faculty of Medicine
- Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis2007 | Faculty of Physical Education and Sport
- Multiple sclerosis - early diagnosis and treatment options2019 | First Faculty of Medicine
- Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration2012 | First Faculty of Medicine
- Prevention of surgical Joint Replacement in the Long-term follow-up of Recent Disease-modifying Drug Trials in OsteoarthritisPublication without faculty affiliation
- Multiple sclerosis2008 | First Faculty of Medicine